PET-CT阴性时对侧肺门N3淋巴结是否需活检
本研究为单中心回顾性队列,纳入1737例连续接受系统EBUS分期的非小细胞肺癌患者,其中1567例肺门N3淋巴结PET-CT阴性,739例经EBUS探查并活检。
要点
- 肺门N3淋巴结PET-CT阴性时,EBUS活检恶性率仅0.68%,低于5%阈值。
- 纵隔N3淋巴结PET-CT阳性者肺门N3隐匿转移风险更高(6.5%)。
- 中度镇静下可考虑从纵隔N3开始,但纵隔N3 PET阳性者应活检肺门N3。
核心结论
- 肺门及纵隔N3淋巴结PET-CT均阴性时,可考虑从纵隔N3开始EBUS分期,跳过肺门N3活检。
- 纵隔N3淋巴结PET-CT阳性者应行肺门N3淋巴结活检。
研究设计与样本
- 回顾性观察性单中心队列研究,纳入1737例连续接受系统EBUS分期的临床影像T1-3、N0-3、M0非小细胞肺癌患者。
主要发现
- 1567例肺门N3淋巴结PET-CT阴性,其中739例经EBUS探查并活检。
- 739例中5例(0.68%;95%CI,0.22%-1.57%)肺门N3淋巴结为恶性。
关键数值与推荐
- 专家意见认为恶性概率低于5%足以跳过肺门N3淋巴结活检。
- 采用二项精确检验比较观察比例与5%阈值。
临床怎么用
- 使用中度镇静时,若肺门及纵隔N3淋巴结PET-CT均阴性,可考虑从纵隔N3开始EBUS分期。
- 纵隔N3淋巴结PET-CT阳性者应行肺门N3淋巴结采样。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systematic endobronchial ultrasound (EBUS)-guided lung cancer staging starts with hilar N3 nodes, proceeding sequentially to mediastinal N3, N2, and N1 nodes, with sampling of all enlarged nodes (size, ≥ 5 mm) by EBUS. However, procedure time is limited by patient comfort when moderate sedation is used. It is unclear if EBUS staging should start with hilar N3 nodes or whether starting with mediastinal N3 nodes suffices. Knowing the probability of hilar N3 nodes with PET-CT scan negative findings harboring occult metastasis can inform this decision. RESEARCH QUESTION: What proportion of patients with hilar N3 nodes showing negative PET-CT scan findings have malignancy by EBUS? STUDY DESIGN AND METHODS: This retrospective observational, single-center cohort study included consecutive patients with clinical-radiographic T1-3, N0-3, M0 non-small cell lung cancer undergoing systematic EBUS staging with biopsy of hilar N3 nodes with negative PET-CT scan findings. The primary outcome was the proportion of patients with malignant hilar N3 nodes showing negative PET-CT scan findings. Based on expert opinion, a threshold probability of malignancy of less than 5% was considered sufficient to skip hilar N3 nodes. We used the binomial exact test to compare the observed proportion vs threshold probability of 5%. RESULTS: Of 1,737 consecutive patients undergoing EBUS staging, 1,567 showed negative PET-CT scan findings of the hilar N3 nodes. These nodes were enlarged by EBUS and were sampled in 739 patients. Malignancy was found in the hilar N3 nodes of 5 of 739 patients (0.68%; 95% CI, 0.22%-1.57%). The proportion was significantly less than the threshold probability (P < .001). Patients with positive PET scan results of the mediastinal N3 nodes were at higher risk of having occult hilar N3 nodal metastasis (P = .003), found in 3 of 46 patients (6.5%; 95% CI, 1.4%-17.9%) with positive PET scan results of the mediastinal N3 nodes. INTERPRETATION: When using moderate sedation, because time is limited, it is reasonable to start with the mediastinal N3 nodes if the hilar and mediastinal N3 nodes show negative PET scan results. Patients with positive PET scan findings of the mediastinal N3 nodes probably should undergo hilar N3 node sampling.
引用
- Sainz Zúñiga PV, Martinez-Zayas G, Molina S, et al. Is Biopsy of Contralateral Hilar N3 Lymph Nodes With Negative PET-CT Scan Findings Necessary When Performing Endobronchial Ultrasound Staging? Chest. 2020. PMID: 33393471. doi:10.1016/j.chest.2020.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。